AML Breakthrough: Can a New Antibody Construct Improve Treatment Outcomes?
"Research suggests a bispecific antibody targeting CD33 could enhance the fight against acute myeloid leukemia by attacking both cancer cells and immune-suppressing cells."
Acute myeloid leukemia (AML) remains a formidable challenge in adult oncology. Despite advancements in treatment, the five-year survival rate lingers below 30%, highlighting the urgent need for innovative therapeutic strategies. Recent research has begun to illuminate the critical role of immune evasion in AML progression and relapse, suggesting that harnessing the immune system could be key to improving patient outcomes.
Among the factors contributing to immune evasion, myeloid-derived suppressor cells (MDSCs) have emerged as significant players. These cells, characterized by their ability to suppress T-cell function, create an environment that shields leukemia cells from immune attack. The presence of MDSCs in AML patients has been linked to poorer responses to therapy and increased risk of relapse, making them an attractive target for novel interventions.
Now, a new study offers a promising approach to targeting MDSCs in AML. Researchers have investigated a CD33/CD3-bispecific antibody construct, which redirects T-cells to eliminate both CD33-expressing AML cells and MDSCs. This dual-targeting strategy holds the potential to overcome immune suppression and enhance the effectiveness of AML therapy. Let's delve into the details of this research and its implications for the future of AML treatment.
AML’s Evolving Treatment Landscape
Acute myeloid leukemia (AML) is a heterogeneous group of malignant clonal disorders originating from hematopoietic stem or progenitor cells, marked by impaired differentiation and uncontrolled proliferation of myeloid cells. The 2021 historical review reports that Food and Drug Administration approval of nine agents for different AML indications has rapidly changed the disease’s prognosis and management. A 2025 historical perspective describes an ongoing, gradual revolution that includes targeted therapies such as tyrosine kinase inhibitors and monoclonal antibodies developed to target AML cells.
What are Myeloid-Derived Suppressor Cells (MDSCs) and Why Do They Matter in AML?
MDSCs are a diverse population of immune cells that share the ability to suppress T-cell responses. In AML, these cells accumulate in the bone marrow and peripheral blood, creating an immunosuppressive environment that protects leukemia cells from immune attack. MDSCs achieve this suppression through various mechanisms, including the production of immunosuppressive molecules like indoleamine-2,3-dioxygenase (IDO) and arginase.
- Reduced response to chemotherapy
- Increased risk of relapse
- Impaired T-cell function
- Suppression of anti-tumor immunity
Emerging Immunotherapeutic Strategies
Recent AML research is exploring next-generation inhibitors, antibody-drug conjugates, and cellular immunotherapies including BiTEs and CAR-T cells. Reviews describe these approaches as part of the continuing pharmacological evolution of AML therapy and link them to the goal of achieving a definitive cure. However, the first-in-human study of the CD33 x CD3 bispecific antibody JNJ-67571244 was terminated after 10 dose-escalation cohorts involving 68 patients, before dose expansion began.
The Limits of Early Bispecific Approaches
The JNJ-67571244 study illustrates the safety challenges facing CD33 x CD3 bispecific antibodies: 11 of 68 patients experienced at least one dose-limiting toxicity, and all experienced at least one treatment-emergent adverse event. Grade 3 or higher treatment-emergent toxicity occurred in 64 patients, or 94.1%, including treatment-related grade 3 or higher toxicity in 28 patients, or 41.2%. At the same time, preclinical work with AMG 330 suggests that CD33/CD3 engagement may produce anti-leukemic activity by directly engaging T cells and targeting CD33-positive monocytic myeloid-derived suppressor cells, while clinical research remains active around CD33, CD123, and CLL-1/CLEC12A.
Standard Care and Newer Options
The established AML management protocol has traditionally used induction chemotherapy followed by consolidation chemotherapy and, for eligible patients, allogeneic stem cell transplantation. The prognosis for patients with relapsed or refractory AML remains unfavorable, creating a need for additional treatment approaches. Comparative treatment discussions examine goals, timing, benefits, harms, monitoring, transplantation or cellular therapy, and clinical trials.
Future Implications for AML Treatment
The study's findings suggest that AMG 330 may offer a dual benefit in AML treatment by directly targeting leukemia cells and simultaneously eliminating immunosuppressive MDSCs. This approach could potentially overcome a significant barrier to effective immunotherapy in AML and improve patient outcomes. Additional research is needed to validate these findings in clinical trials and to explore the potential of combining AMG 330 with other immunotherapeutic strategies.
A Broader Therapeutic Shift
A 2023 literature review describes a paradigm shift in AML treatment and prognosis during the previous 20 years. It attributes this shift to new drugs and approaches, including gemtuzumab ozogamicin, CPX-351, hypomethylating agents, and venetoclax. The review also identifies optimized conditioning regimens in allogeneic hematopoietic stem cell transplantation as part of this development.
Persistent Resistance and Relapse
Progress in immunotherapy has been substantially greater for B-cell lymphoid malignancies and multiple myeloma than for AML over the past decade. Reviews nevertheless describe several AML immunotherapy strategies as under investigation. Resistance to chemotherapy and disease relapse remain principal obstacles to successful treatment.
Treatment Burden and Patient Outcomes
AML is described as the most common acute leukemia in adults, with increasing incidence with age and a persistently poor five-year outlook. Despite significant advances, AML still has a dismal prognosis for too many patients. In many cases, a cure can be achieved only after allogeneic hematopoietic stem cell transplantation, a procedure associated with severe treatment-related complications.